Development and evaluation of psychotropic drugs
Development and evaluation of psychotropic drugs
Existing pharmacological treatments for mental disorders are not ideal, and there is much scope for the development of new compounds likely to be associated with improved effectiveness and acceptability in clinical practice. The appearance of a novel psychotropic drug treatment is the result of many years of diligent work from pre-clinical and clinical scientists and considerable scrutiny from regulatory bodies. Most compounds with the potential for clinical use do not enter the comparatively late stage of randomized controlled trials, and some medications are withdrawn from use once safety and tolerability problems are identified in routine clinical samples. This contribution describes the phases of psychotropic drug development, highlights some aspects of study design in the evaluation of potential treatments prior to licensing, and considers likely future challenges in this research environment.
psychotropic drugs, evaluation, anxiety, depression, drug development, placebo, psychopharmacology, randomized controlled trials
279-283
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a
July 2007
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a
Abstract
Existing pharmacological treatments for mental disorders are not ideal, and there is much scope for the development of new compounds likely to be associated with improved effectiveness and acceptability in clinical practice. The appearance of a novel psychotropic drug treatment is the result of many years of diligent work from pre-clinical and clinical scientists and considerable scrutiny from regulatory bodies. Most compounds with the potential for clinical use do not enter the comparatively late stage of randomized controlled trials, and some medications are withdrawn from use once safety and tolerability problems are identified in routine clinical samples. This contribution describes the phases of psychotropic drug development, highlights some aspects of study design in the evaluation of potential treatments prior to licensing, and considers likely future challenges in this research environment.
This record has no associated files available for download.
More information
Published date: July 2007
Keywords:
psychotropic drugs, evaluation, anxiety, depression, drug development, placebo, psychopharmacology, randomized controlled trials
Identifiers
Local EPrints ID: 62286
URI: http://eprints.soton.ac.uk/id/eprint/62286
PURE UUID: 901f3a5c-f43b-4c4d-adbf-c9d4e3a60501
Catalogue record
Date deposited: 12 Sep 2008
Last modified: 16 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
Khalil Ajel
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
